ras genes

Summary

Summary: Family of retrovirus-associated DNA sequences (ras) originally isolated from Harvey (H-ras, Ha-ras, rasH) and Kirsten (K-ras, Ki-ras, rasK) murine sarcoma viruses. Ras genes are widely conserved among animal species and sequences corresponding to both H-ras and K-ras genes have been detected in human, avian, murine, and non-vertebrate genomes. The closely related N-ras gene has been detected in human neuroblastoma and sarcoma cell lines. All genes of the family have a similar exon-intron structure and each encodes a p21 protein.

Top Publications

  1. ncbi Hyperactive Ras in developmental disorders and cancer
    Suzanne Schubbert
    Department of Pediatrics, University of California, 513 Parnassus Avenue, Room HSE 302, San Francisco, California 94143, USA
    Nat Rev Cancer 7:295-308. 2007
  2. ncbi K-ras mutations and benefit from cetuximab in advanced colorectal cancer
    Christos S Karapetis
    Flinders Medical Centre and Flinders University, Adelaide, Australia
    N Engl J Med 359:1757-65. 2008
  3. ncbi Tumour biology: senescence in premalignant tumours
    Manuel Collado
    Spanish National Cancer Centre CNIO, Madrid 28029, Spain
    Nature 436:642. 2005
  4. ncbi Somatic activation of the K-ras oncogene causes early onset lung cancer in mice
    L Johnson
    Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
    Nature 410:1111-6. 2001
  5. ncbi BRAF and RAS mutations in human lung cancer and melanoma
    Marcia S Brose
    Department of Medicine, Abramson Family Cancer Research Institute, University of Pennsylvania Cancer Center, Philadelphia 19104, USA
    Cancer Res 62:6997-7000. 2002
  6. ncbi Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status
    Harith Rajagopalan
    Sidney Kimmel Comprehensive Cancer Centre, Howard Hughes Medical Institution and Program in Cellular and Molecular Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Nature 418:934. 2002
  7. pmc Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells
    B Elenbaas
    Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA
    Genes Dev 15:50-65. 2001
  8. pmc Ras oncogenes: split personalities
    Antoine E Karnoub
    Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA
    Nat Rev Mol Cell Biol 9:517-31. 2008
  9. pmc Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
    E L Jackson
    Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
    Genes Dev 15:3243-8. 2001
  10. pmc BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum
    T Kambara
    Conjoint Gastroenterology Laboratory, Royal Brisbane and Women s Hospital Research Foundation and Queensland Institute of Medical Research, Brisbane 4029, Australia
    Gut 53:1137-44. 2004

Detail Information

Publications374 found, 100 shown here

  1. ncbi Hyperactive Ras in developmental disorders and cancer
    Suzanne Schubbert
    Department of Pediatrics, University of California, 513 Parnassus Avenue, Room HSE 302, San Francisco, California 94143, USA
    Nat Rev Cancer 7:295-308. 2007
    b>Ras genes are the most common targets for somatic gain-of-function mutations in human cancer...
  2. ncbi K-ras mutations and benefit from cetuximab in advanced colorectal cancer
    Christos S Karapetis
    Flinders Medical Centre and Flinders University, Adelaide, Australia
    N Engl J Med 359:1757-65. 2008
    ..The mutation status of the K-ras gene in the tumor may affect the response to cetuximab and have treatment-independent prognostic value...
  3. ncbi Tumour biology: senescence in premalignant tumours
    Manuel Collado
    Spanish National Cancer Centre CNIO, Madrid 28029, Spain
    Nature 436:642. 2005
    ..Senescence is therefore a defining feature of premalignant tumours that could prove valuable in the diagnosis and prognosis of cancer...
  4. ncbi Somatic activation of the K-ras oncogene causes early onset lung cancer in mice
    L Johnson
    Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
    Nature 410:1111-6. 2001
    ..This approach has several advantages over traditional transgenic strategies, including that it more closely recapitulates spontaneous oncogene activation as seen in human cancers...
  5. ncbi BRAF and RAS mutations in human lung cancer and melanoma
    Marcia S Brose
    Department of Medicine, Abramson Family Cancer Research Institute, University of Pennsylvania Cancer Center, Philadelphia 19104, USA
    Cancer Res 62:6997-7000. 2002
    ..Although uncommon, BRAF mutations in human lung cancers may identify a subset of tumors sensitive to targeted therapy...
  6. ncbi Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status
    Harith Rajagopalan
    Sidney Kimmel Comprehensive Cancer Centre, Howard Hughes Medical Institution and Program in Cellular and Molecular Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Nature 418:934. 2002
    ....
  7. pmc Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells
    B Elenbaas
    Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA
    Genes Dev 15:50-65. 2001
    ..Thus, these observations establish an experimental system for elucidating both the genetic and cell biological requirements for the development of breast cancer...
  8. pmc Ras oncogenes: split personalities
    Antoine E Karnoub
    Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA
    Nat Rev Mol Cell Biol 9:517-31. 2008
    ....
  9. pmc Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
    E L Jackson
    Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
    Genes Dev 15:3243-8. 2001
    ..Of particular significance, this system has led to the identification of a new cell type contributing to the development of pulmonary adenocarcinoma...
  10. pmc BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum
    T Kambara
    Conjoint Gastroenterology Laboratory, Royal Brisbane and Women s Hospital Research Foundation and Queensland Institute of Medical Research, Brisbane 4029, Australia
    Gut 53:1137-44. 2004
    ..However, the distribution of BRAF mutations in MSI-H cancers remains to be clarified with respect to precursor lesions and the CpG island methylator phenotype (CIMP)...
  11. ncbi Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes
    C Almoguera
    Department of Biochemistry, State University of New York, Stony Brook 11794
    Cell 53:549-54. 1988
    ..chain reaction (PCR) and mutation detection by the RNAase A mismatch cleavage method, we have examined c-K-ras genes in human pancreatic carcinomas...
  12. ncbi Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications
    Takayuki Kosaka
    Departments of Thoracic Surgery and Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan
    Cancer Res 64:8919-23. 2004
    ..EGFR mutations define a distinct subset of pulmonary adenocarcinoma without KRAS mutations, which is not caused by tobacco carcinogens...
  13. ncbi KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
    Astrid Lievre
    Universite Paris Descartes, Institut National de la Sante et de la Recherche Medicale UMR 775, Paris, France
    Cancer Res 66:3992-5. 2006
    ..The EGFR amplification, which is not as frequent as initially reported, is also associated with response to this treatment...
  14. pmc KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
    William Pao
    Program in Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    PLoS Med 2:e17. 2005
    ..Lung adenocarcinomas also harbor activating mutations in the downstream GTPase, KRAS, and mutations in EGFR and KRAS appear to be mutually exclusive...
  15. ncbi The dark side of Ras: regulation of apoptosis
    Adrienne D Cox
    Department of Pharmacology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Oncogene 22:8999-9006. 2003
    ....
  16. ncbi Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication
    Raffaella Di Micco
    IFOM Foundation FIRC Institute of Molecular Oncology Foundation, 20139 Milan, Italy
    Nature 444:638-42. 2006
    ..Last, we show that oncogene activation is associated with DDR activation in a mouse model in vivo. We propose that OIS results from the enforcement of a DDR triggered by oncogene-induced DNA hyper-replication...
  17. ncbi RAS oncogenes: the first 30 years
    Marcos Malumbres
    Molecular Oncology Programme, Centro Nacional de Investigaciones Oncologicas, Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    Nat Rev Cancer 3:459-65. 2003
    From the pioneering work with acute transforming retroviruses to the current post-genomic era, RAS genes have always been at the leading edge of signal transduction and molecular oncology...
  18. ncbi Targeting RAS signalling pathways in cancer therapy
    Julian Downward
    Cancer Research UK, London Research Institute, 44 Lincoln s Inn Fields, London WC2A 3PX, UK
    Nat Rev Cancer 3:11-22. 2003
    ..They are aberrant in most human tumours due to activating mutations in the RAS genes themselves or to alterations in upstream or downstream signalling components...
  19. ncbi Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer
    Eric Van Cutsem
    University Hospital Gasthuisberg, Digestive Oncology Unit, Herestraat 49, 3000 Leuven, Belgium
    N Engl J Med 360:1408-17. 2009
    ....
  20. ncbi Blocking oncogenic Ras signaling for cancer therapy
    A A Adjei
    Division of Medical Oncology Mayo Clinic and Foundation, Rochester, MN 55905, USA
    J Natl Cancer Inst 93:1062-74. 2001
    ..Novel cancer therapeutic approaches based on the inhibition of Ras-mediated signaling, including inhibition of Ras processing, inhibition of Ras protein synthesis, and blockage of downstream Ras effectors, will be discussed...
  21. pmc Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study
    H J Andreyev
    Department of Medicine and Therapeutics, Imperial College School of Medicine, Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH, UK
    Br J Cancer 85:692-6. 2001
    ....
  22. pmc PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer
    Shuji Ogino
    Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, 44 Binney St, Room JF 215C, Boston, MA 02115 USA
    J Clin Oncol 27:1477-84. 2009
    ..PIK3CA mutation and subsequent activation of the AKT pathway play an important role in colorectal carcinogenesis. However, little is known about the prognostic role of PIK3CA mutation in colon cancer...
  23. ncbi Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
    Helena Linardou
    1st Department of Medical Oncology, Metropolitan Hospital, Athens, Greece
    Lancet Oncol 9:962-72. 2008
    ..The aim of this systematic review and meta-analysis was to assess if k-RAS mutations represent a candidate predictive biomarker for anti-EGFR-targeted therapeutic strategies in mCRC and NSCLC...
  24. ncbi Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context
    Carmen Guerra
    Molecular Oncology Programme, Centro Nacional de Investigaciones Oncologicas CNIO, Melchor Fernandez Almagro 3, 28029, Madrid, Spain
    Cancer Cell 4:111-20. 2003
    ..These results indicate that neoplastic growth induced by an endogenous K-ras oncogene depends upon cellular context...
  25. pmc Recurrent KRAS codon 146 mutations in human colorectal cancer
    Sarah Edkins
    Cancer Genome Project, Welcome Trust Sanger Institute, Hinxton, UK
    Cancer Biol Ther 5:928-32. 2006
    ....
  26. ncbi Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects
    David A Tuveson
    Abramson Family Cancer Research Institute, Abramson Cancer Center and Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104 USA
    Cancer Cell 5:375-87. 2004
    ..Our results suggest that endogenous oncogenic ras is sufficient to initiate transformation by stimulating proliferation, while further genetic lesions may be necessary for progression to frank malignancy...
  27. ncbi Increasing complexity of Ras signaling
    S L Campbell
    Department of Biochemistry and Biophysics, MIT, Cambridge, Massachusetts 02139, USA
    Oncogene 17:1395-413. 1998
    The initial discovery that ras genes endowed retroviruses with potent carcinogenic properties and the subsequent determination that mutated ras genes were present in a wide variety of human cancers, prompted a strong suspicion that the ..
  28. ncbi Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib
    David A Eberhard
    Department of Pathology, Genentech Inc, San Francisco, CA, USA
    J Clin Oncol 23:5900-9. 2005
    ..KRAS is frequently activated in NSCLC. The relationship of KRAS mutations to outcome after EGFR inhibitor treatment has not been described...
  29. pmc The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis
    C Mascaux
    Department of Intensive Care and Thoracic Oncology, Institut Jules Bordet, Centre des Tumeurs de l Universite Libre de Bruxelles, Belgium
    Br J Cancer 92:131-9. 2005
    ..40; 95% CI 1.18-1.65) but not in studies using IHC (HR 1.08; 95% CI 0.86-1.34). RAS appears to be a pejorative prognostic factor in terms of survival in NSCLC globally, in ADC and when it is studied by PCR...
  30. pmc Activated oncogenes promote and cooperate with chromosomal instability for neoplastic transformation
    Richard A Woo
    Department of Biochemistry, Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong
    Genes Dev 18:1317-30. 2004
    ..These data indicate that chromosomal instability could be a catalyst for oncogenic transformation, and bring together aspects of the chromosomal instability hypothesis and the gene mutation hypothesis for tumorigenesis...
  31. ncbi Mutations of epidermal growth factor receptor and K-ras genes in adenosquamous carcinoma of the lung
    Shinichi Toyooka
    Int J Cancer 118:1588-90. 2006
  32. ncbi Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification
    B Angulo
    Lung Cancer Group, Spanish National Cancer Centre CNIO, 28029 Madrid, Spain
    J Pathol 214:347-56. 2008
    ..Moreover, our cDNA microarray analysis identified increased PIK3CA expression due to gene amplification in lung squamous cell carcinomas: this may represent a marker of sensitivity to therapy with PI3K inhibitors...
  33. pmc While K-ras is essential for mouse development, expression of the K-ras 4A splice variant is dispensable
    Sarah J Plowman
    Sir Alastair Currie Cancer Research UK Laboratories, Molecular Medicine Centre, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, Scotland, U K
    Mol Cell Biol 23:9245-50. 2003
    In mammals, the three classical ras genes encode four highly homologous proteins, N-Ras, H-Ras, and the isoforms K-Ras 4A and 4B...
  34. ncbi PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies
    Andrea Sartore-Bianchi
    The Falck Division of Medical Oncology, Ospedale Niguarda Ca Granda, Milan, Italy
    Cancer Res 69:1851-7. 2009
    ..When the molecular status of the PIK3CA/PTEN and KRAS pathways are concomitantly ascertained, up to 70% of mCRC patients unlikely to respond to EGFR moAbs can be identified...
  35. ncbi Quantitative analysis of K-ras gene mutation in pancreatic tissue obtained by endoscopic ultrasonography-guided fine needle aspiration: clinical utility for diagnosis of pancreatic tumor
    Minoru Tada
    Department of Gastroenterology, Faculty of Medicine, University of Tokyo, Japan
    Am J Gastroenterol 97:2263-70. 2002
    ..The combination of pathological diagnosis and analysis for mutant K-ras gene was investigated to improve the accuracy of diagnosis...
  36. ncbi The Ras radiation resistance pathway
    A K Gupta
    Department of Radiation Oncology, University of Pennsylvania, 195 John Morgan Building, 3620 Hamilton Walk, Philadelphia, PA 19104, USA
    Cancer Res 61:4278-82. 2001
    ..These experiments have indicated the importance of PI3K in mediating enhanced radioresistance and have implicated PI3K as a potential target for specific radiosensitization of tumors...
  37. ncbi Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance
    Kian Huat Lim
    Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer Cell 8:381-92. 2005
    ..Thus, as tumorigenesis progresses the addiction of cancers to their initiating oncogene is reduced to, at least in the case of Ras, the PI3K/AKT pathway...
  38. ncbi Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation
    Z T Zhang
    Department of Urology, New York University School of Medicine, New York, NY 10016, USA
    Oncogene 20:1973-80. 2001
    ....
  39. pmc Digital PCR
    B Vogelstein
    The Howard Hughes Medical Institute and The Johns Hopkins Oncology Center, Baltimore, MD 21231, USA
    Proc Natl Acad Sci U S A 96:9236-41. 1999
    ..The process provides a reliable and quantitative measure of the proportion of variant sequences within a DNA sample...
  40. ncbi Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines
    E J Bernhard
    Department of Radiation Oncology, University of Pennsylvania, Philadelphia 19104 6072, USA
    Cancer Res 60:6597-600. 2000
    ..These findings support the development of strategies that target ras for inactivation in the treatment of cancer...
  41. ncbi Oncogene-induced senescence as an initial barrier in lymphoma development
    Melanie Braig
    Charité Universitätsmedizin Berlin Haematology Oncology, 13353 Berlin, Germany
    Nature 436:660-5. 2005
    ..These results identify H3K9me-mediated senescence as a novel Suv39h1-dependent tumour suppressor mechanism whose inactivation permits the formation of aggressive but apoptosis-competent lymphomas in response to oncogenic Ras...
  42. ncbi Implications of NRAS mutations in AML: a study of 2502 patients
    Ulrike Bacher
    Munich Leukemia Laboratory, Department of Internal Medicine III, University Hospital Munich, Ludwig Maximilians University, Max Lebsche Platz 31, 81377 Munich, Germany
    Blood 107:3847-53. 2006
    ..However, there was a trend to better survival in most subgroups, especially when other molecular markers (FLT3-LM, MLL-PTD, and NPM) were taken into account...
  43. ncbi Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation
    A Paz
    Department of Neurobiochemistry, The George S Wise Faculty of Life Sciences, Tel Aviv University, 69978 Tel Aviv, Israel
    Oncogene 20:7486-93. 2001
    b>Ras genes, frequently mutated in human tumors, promote malignant transformation. Ras transformation requires membrane anchorage, which is promoted by Ras farnesylcysteine carboxymethylester and by a second signal...
  44. pmc K-ras is an essential gene in the mouse with partial functional overlap with N-ras
    L Johnson
    Department of Biology, Massachusetts Institute of Technology, Cambridge 02139, USA
    Genes Dev 11:2468-81. 1997
    Mammalian ras genes are thought to be critical in the regulation of cellular proliferation and differentiation and are mutated in approximately 30% of all human tumors. However, N-ras and H-ras are nonessential for mouse development...
  45. ncbi PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients
    F Perrone
    Experimental Molecular Pathology, Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
    Ann Oncol 20:84-90. 2009
    ....
  46. ncbi The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS
    Daisy Wing Sze Wong
    Department of Pathology, University of Hong Kong, Queen Mary Hospital, Hong Kong Special Administrative Region, China
    Cancer 115:1723-33. 2009
    ..The authors of this study investigated the frequency, genetic and clinicopathologic profiles of EML4-ALK in Chinese patients with NSCLC...
  47. ncbi Associations between cigarette smoking, lifestyle factors, and microsatellite instability in colon tumors
    M L Slattery
    Health Research Center, Department of Family and Preventive Medicine, University of Utah, Salt Lake City, USA
    J Natl Cancer Inst 92:1831-6. 2000
    ..It is unknown whether lifestyle factors associated with colon cancer, such as physical activity, body size, cigarette smoking, or use of aspirin and/or nonsteroidal anti-inflammatory drugs, contribute to MSI in sporadic tumors...
  48. pmc Reversal of human cellular senescence: roles of the p53 and p16 pathways
    Christian M Beausejour
    Lawrence Berkeley National Laboratory, MS 84 171, 1 Cyclotron Road, Berkeley, CA 94720, USA
    EMBO J 22:4212-22. 2003
    ..Our results indicate that the senescence response to telomere dysfunction is reversible and is maintained primarily by p53. However, p16 provides a dominant second barrier to the unlimited growth of human cells...
  49. ncbi Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer
    Ming Sound Tsao
    Department of Hematology and Oncology, Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada
    J Clin Oncol 25:5240-7. 2007
    ....
  50. ncbi K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study
    Mirian Brink
    Nutrition and Toxicology Research Institute Maastricht NUTRIM, Department of Epidemiology, Maastricht University, PO Box 616, The Netherlands
    Carcinogenesis 24:703-10. 2003
    ....
  51. pmc Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK
    Alice T Shaw
    Department of Pathology, Massachusetts General Hospital, Warren 501c, 55 Fruit St, Boston, MA 02114, USA
    J Clin Oncol 27:4247-53. 2009
    ..To aid in identification and treatment of these patients, we examined the clinical characteristics and treatment outcomes of patients who had NSCLC with and without EML4-ALK...
  52. ncbi The superoxide-generating oxidase Nox1 is functionally required for Ras oncogene transformation
    Junji Mitsushita
    Department of Molecular Biology and Biochemistry, Shinshu University School of Medicine, Matsumoto, Nagano, Japan
    Cancer Res 64:3580-5. 2004
    ..Therefore, we propose that increased reactive oxygen species generation by Ras-induced Nox1 is required for oncogenic Ras transformation...
  53. pmc Activating transcription factor 3, a stress sensor, activates p53 by blocking its ubiquitination
    Chunhong Yan
    Department of Cancer Biology, MD Anderson Cancer Center, Houston, TX 77030, USA
    EMBO J 24:2425-35. 2005
    ....
  54. ncbi A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis
    M Llanos Casanova
    Project on Cell and Molecular Biology and Gene Therapy, Centro de Investigaciones Energeticas, Medioambientales y Tecnologicas, 28040 Madrid, Spain
    Cancer Res 62:3402-7. 2002
    ..It is tempting to speculate that EGFR family members may function as angiogenic regulators in other epithelial tumors such as those of the colon, breast, and prostate, reinforcing their value as targets for therapeutic intervention...
  55. pmc p53 mutations in human cutaneous melanoma correlate with sun exposure but are not always involved in melanomagenesis
    S F Zerp
    Department of Clinical Oncology, University Hospital, Leiden, The Netherlands
    Br J Cancer 79:921-6. 1999
    ....
  56. ncbi BRAF mutations in metastatic melanoma: a possible association with clinical outcome
    Rajiv Kumar
    Department of Biosciences, Karolinska Institute, Novum, 141 57 Huddinge, Sweden
    Clin Cancer Res 9:3362-8. 2003
    ..Recently, activating mutations in the BRAF gene, were reported in a large proportion of melanomas. We have studied mutations in the BRAF gene and their association with clinical parameters...
  57. ncbi Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies
    Silvia Benvenuti
    Laboratory of Molecular Genetics, Institute for Cancer Research and Treatment, University of Torino Medical School, Candiolo, Italy
    Cancer Res 67:2643-8. 2007
    ..They also provide the rationale for combination therapies, targeted simultaneously to the EGFR and RAS/RAF/MAPK signaling pathways in CRC patients...
  58. pmc PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab
    Minaxi Jhawer
    Department of Oncology, Montefiore Medical Center, Albert Einstein Cancer Center, Bronx, NY 10467, USA
    Cancer Res 68:1953-61. 2008
    ..A priori screening of colon tumors for PTEN expression status and PIK3CA and Ras/BRAF mutation status could help stratify patients likely to benefit from this therapy...
  59. ncbi Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation
    Sae Won Han
    Department of Internal Medicine and Pathology, Seoul National University Hospital, and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
    Clin Cancer Res 12:2538-44. 2006
    ....
  60. pmc A negative feedback signaling network underlies oncogene-induced senescence
    Stéphanie Courtois-Cox
    Genetics Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 458c NRB, 77 Louis Pasteur Avenue, Boston, Massachusetts 02115, USA
    Cancer Cell 10:459-72. 2006
    ..Thus, the ultimate response to the aberrant activation of the Ras pathway is a multifaceted negative feedback signaling network that terminates the oncogenic signal and participates in the senescence response...
  61. ncbi Oncogenic Ras sensitizes normal human cells to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis
    Alexandre Nesterov
    Division of Medical Oncology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Cancer Res 64:3922-7. 2004
    ....
  62. pmc Mutations in APC, Kirsten-ras, and p53--alternative genetic pathways to colorectal cancer
    Gillian Smith
    Cancer Research United Kingdom Molecular Pharmacology Unit, Biomedical Research Centre, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, United Kingdom
    Proc Natl Acad Sci U S A 99:9433-8. 2002
    ....
  63. ncbi Mutant KRAS, chromosomal instability and prognosis in colorectal cancer
    Patrizio Castagnola
    National Institute for Cancer Research, Largo R Benzi, 10, 16132 Genoa, Italy
    Biochim Biophys Acta 1756:115-25. 2005
    ..This review addresses the controversial link of KRAS mutations in colorectal cancer with chromosomal instability and patient prognosis...
  64. pmc Sequential activation of the MEK-extracellular signal-regulated kinase and MKK3/6-p38 mitogen-activated protein kinase pathways mediates oncogenic ras-induced premature senescence
    Weiping Wang
    Department of Molecular Biology, The Scripps Research Institute, La Jolla, California 91037, USA
    Mol Cell Biol 22:3389-403. 2002
    ..These studies have defined the molecular events within the ras signaling cascade that lead to premature senescence and, thus, have provided new insights into how ras confers oncogenic transformation in primary cells...
  65. pmc Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis
    Brooke Ancrile
    Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Genes Dev 21:1714-9. 2007
    ..IL6 appears to act in a paracrine fashion to promote angiogenesis and tumor growth. Inhibiting IL6 may therefore have therapeutic utility for treatment of cancers characterized by oncogenic Ras mutations...
  66. pmc The Ras-association domain family (RASSF) members and their role in human tumourigenesis
    Louise van der Weyden
    Experimental Cancer Genetics Laboratory, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton Cambridge, UK
    Biochim Biophys Acta 1776:58-85. 2007
    ....
  67. ncbi Molecular detection of APC, K- ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers
    Jaw Yuan Wang
    MedicoGenomic Research Center, Kaohsiung Medical University, No 100, Shih Chuan 1st Road, 807 Kaohsiung, Taiwan
    World J Surg 28:721-6. 2004
    ..Moreover, these genes may be potential molecular markers of poor clinical outcome in CRC patients...
  68. ncbi c-fos is required for malignant progression of skin tumors
    E Saez
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cell 82:721-32. 1995
    ..These results demonstrate that a member of the AP-1 family of transcription factors is required for the development of a malignant tumor...
  69. ncbi Influence of single nucleotide polymorphisms in H-Ras and cyclin D1 genes on oral cancer susceptibility
    K M Sathyan
    Division of Cancer Research, Regional Cancer Centre, Thiruvananthapuram 695011, Kerala, India
    Oral Oncol 42:607-13. 2006
    ....
  70. ncbi Animal products and K-ras codon 12 and 13 mutations in colon carcinomas
    E Kampman
    Division of Human Nutrition and Epidemiology, Wageningen University, Dreijenlaan 1 BODE 154, 6703 HA Wageningen, The Netherlands
    Carcinogenesis 21:307-9. 2000
    ..6 (0. 3-1.2)]. Transition and transversion mutations were not differently associated with these dietary factors. These data suggest a different dietary aetiology of colon tumours harbouring K-ras codon 12 and 13 mutations...
  71. ncbi Absence of BRAF and NRAS mutations in uveal melanoma
    Frank Cruz
    Oregon Health and Science University OHSU Cancer Institute, Department of Pathology, OHSU and Portland Veterans Affairs Medical Center, Portland, Oregon 97239, USA
    Cancer Res 63:5761-6. 2003
    ..No NRAS exon 1 mutations were detected in either type of melanoma. We conclude that UMs arise independent of oncogenic BRAF and NRAS mutations, an observation that may have implications for therapies targeted to the NRAS-BRAF pathway...
  72. ncbi Paradoxical tumor inhibitory effect of p53 loss in transgenic mice expressing epidermal-targeted v-rasHa, v-fos, or human transforming growth factor alpha
    D A Greenhalgh
    Department of Cell Biology, Baylor College of Medicine, Houston, Texas 77030, USA
    Cancer Res 56:4413-23. 1996
    ..Alternatively, there may be a requirement forp53 expression in response to TPA or a wound-promotion stimulus in mouse epidermis...
  73. ncbi Laterally spreading type of colorectal adenoma exhibits a unique methylation phenotype and K-ras mutations
    Sakiko Hiraoka
    Department of Gastroenterology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
    Gastroenterology 131:379-89. 2006
    ..Laterally spreading tumors (LST), characterized by superficial extension along the colonic lumen, have recently been detected by colonoscopy. However, genetic and epigenetic characteristics of these tumors were scarcely reported...
  74. pmc Detection of rare mutant K-ras DNA in a single-tube reaction using peptide nucleic acid as both PCR clamp and sensor probe
    Ji Dung Luo
    Department of Medical Biotechnology and Laboratory Science, Chang Gung University, Taoyuan 333, Taiwan
    Nucleic Acids Res 34:e12. 2006
    ..Taken together, our data suggest that this newly devised protocol can serve as an useful tool for cancer screening as well as in the detection of rare mutation in many diseases...
  75. ncbi Different types of K-Ras mutations are conversely associated with overall survival in patients with colorectal cancer
    Thomas Winder
    Department of Medicine, Academic Teaching Hospital Feldkirch, A 6807 Feldkirch, Austria
    Oncol Rep 21:1283-7. 2009
    ..44 (0.2-0.99)]. In conclusion, for the first time, our study showed clearly that different types of K-Ras mutations are conversely associated with overall survival in patients with colorectal cancer...
  76. pmc Mutations of K-ras oncogene in human adrenal tumours in Taiwan
    S R Lin
    Department of Clinical Pathology, Kaohsiung Medical College, Taiwan
    Br J Cancer 77:1060-5. 1998
    ..For the ras oncogenes analysed, exon 1 to exon 2 of H-ras and K-ras genes in the tumour tissues of 13 Conn's syndrome, two adrenal Cushing's syndrome, two non-functional adrenal tumours, ..
  77. pmc p53 and K-ras gene mutations in carcinoma of the rectum among Finnish women
    K Servomaa
    North Savo Regional Environment Centre, Kuopio, Finland
    Mol Pathol 53:24-30. 2000
    ..The aim of this study was to identify p53 and K-ras gene mutations in carcinoma of the rectum among Finnish women. Mutation patterns might give clues to aetiological factors when comparisons are made with other human tumours...
  78. ncbi K-ras mutations and RASSF1A promoter methylation in colorectal cancer
    Manon van Engeland
    Department of Pathology, University Maastricht, P O Box 616 6200 MD Maastricht, The Netherlands
    Oncogene 21:3792-5. 2002
    ..These data show that the majority of the studied CRCs with K-ras mutations lack RASSF1A promoter methylation, an event which occurs predominantly in K-ras wild-type CRCs (P=0.023, Chi-square test)...
  79. ncbi APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance
    Jan Sing Hsieh
    Department of Surgery, Kaohsiung Medical University, Kaohsiung, Taiwan
    Am Surg 71:336-43. 2005
    ..Serial analysis is warranted in order to assess their long-term prognostic significance and the therapeutic implications...
  80. pmc Detection of Ki-ras mutations in tissue and plasma samples of patients with pancreatic cancer using PNA-mediated PCR clamping and hybridisation probes
    J Däbritz
    Charite Universitatsmedizin Berlin, Campus Virchow Klinikum, Medizinische Klinik und Poliklinik m S Hämatologie und Onkologie, Augustenburger Platz 1, 13353 Berlin, Germany
    Br J Cancer 92:405-12. 2005
    ..In addition, this method can be adapted for simultanous detection of multiple mutations and quantitation...
  81. pmc Pathological and molecular progression of astrocytomas in a GFAP:12 V-Ha-Ras mouse astrocytoma model
    Patrick Shannon
    Department of Neuropathology, The University of Toronto, Toronto, Ontario, Canada, M5T 2S8
    Am J Pathol 167:859-67. 2005
    ..Of interest, many of these acquired alterations occur in human astrocytomas, further validating GFAP-RAS as a useful model for studying astrocytoma development and progression...
  82. pmc Molecular characteristics of serrated adenomas of the colorectum
    E J Sawyer
    Molecular and Population Genetics Laboratory, Imperial Cancer Research Fund, London WC2A 3PX, UK
    Gut 51:200-6. 2002
    ....
  83. ncbi Mutations in the BRAF and N-ras genes in childhood acute lymphoblastic leukaemia
    B Gustafsson
    Leukemia 19:310-2. 2005
  84. pmc Microsatellite instability and the clinicopathological features of sporadic colorectal cancer
    R Ward
    Department of Medical Oncology, St Vincent s Hospital, Victoria St, Darlinghurst, NSW, 2010, Australia
    Gut 48:821-9. 2001
    ....
  85. pmc Meat consumption and K-ras mutations in sporadic colon and rectal cancer in The Netherlands Cohort Study
    M Brink
    Nutrition and Toxicology Research Institute Maastricht NUTRIM, Department of Epidemiology, Maastricht University, PO Box 616, 6200 MD, Maastricht, The Netherlands
    Br J Cancer 92:1310-20. 2005
    ....
  86. ncbi Detection of codon 61 point mutations of the K-ras gene in lung and colorectal cancers by enriched PCR
    Shinichi Toyooka
    Department of Cancer and Thoracic Surgery, Graduate School of Medicine and Dentistry, Okayama University, Okayama 700 8558, Japan
    Oncol Rep 10:1455-9. 2003
    ....
  87. ncbi Relationship of Ras association domain family 1 methylation and K-ras mutation in primary non-small cell lung cancer
    Duk Hwan Kim
    Center for Genomics Research, Samsung Biomedical Research Institute, Room B155, 50 Ilwon Dong, Kangham ku, 135 710 Seoul, Korea
    Cancer Res 63:6206-11. 2003
    ..In addition, RASSF1A methylation, in combination with K-ras mutation, may have an adverse synergistic effect on patient's survival in NSCLCs...
  88. ncbi A modified mutagenic PCR-RFLP method for K-ras codon 12 and 13 mutations detection in NSCLC patients
    A Hatzaki
    Molecular Biology Department, Hygeia Diagnostic and Therapeutic Centre of Athens, 4 Erythrou Stavrou and Kifissias Ave, 15123, Athens, Greece
    Mol Cell Probes 15:243-7. 2001
    ..We provide evidence that our approach is a fast and reliable method for screening K- ras exon 1 mutations in tumour samples from NSCLC patients...
  89. ncbi Amplification of wild-type K-ras promotes growth of head and neck squamous cell carcinoma
    Michael Hoa
    Department of Otolaryngology Head and Neck Surgery, Cancer Research Center, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Cancer Res 62:7154-6. 2002
    ..These novel findings may have important ramifications for potential K-ras-targeted interventions in the treatment of HNSCC...
  90. ncbi A genetically defined model for human ovarian cancer
    Jinsong Liu
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 64:1655-63. 2004
    ..These cells provide a novel model system to study human ovarian cancer...
  91. pmc The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence
    Frédérick A Mallette
    Departement de Biochimie, Universite de Montreal, Montreal, Quebec H3C 3J7, Canada
    Genes Dev 21:43-8. 2007
    ..Intriguingly, bypassing oncogene-induced senescence by inactivation of p53 and Rb did not eliminate the accumulation of oncogene-induced DNA damage foci (ODDI), suggesting a mechanism that may limit transformation in immortalized cells...
  92. ncbi Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer
    C Bengala
    Division of Medical Oncology, Department of Oncology and Hematology, University of Modena and Reggio Emilia, Modena, Italy
    Ann Oncol 20:469-74. 2009
    ....
  93. ncbi Identification of bronchioalveolar stem cells in normal lung and lung cancer
    Carla F Bender Kim
    Center for Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
    Cell 121:823-35. 2005
    ..Although bronchiolar cells and alveolar cells are proposed to be the precursor cells of adenocarcinoma, this work points to BASCs as the putative cells of origin for this subtype of lung cancer...
  94. ncbi FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma
    Adel H Jebar
    Cancer Research UK Clinical Centre, St James s University Hospital, Beckett Street, Leeds LS9 7TF, UK
    Oncogene 24:5218-25. 2005
    ..These included mutations in all three Ras genes; ten in HRAS, four in KRAS2 and four in NRAS and these were not associated with either tumour grade or stage...
  95. pmc Cooperative effects of INK4a and ras in melanoma susceptibility in vivo
    L Chin
    Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    Genes Dev 11:2822-34. 1997
    ..In addition, this mouse model affords a system in which to identify and analyze pathways involved in tumor progression against the backdrop of genetic alterations encountered in human melanomas...
  96. ncbi Compartmentalized Ras/MAPK signaling
    Adam Mor
    Department of Medicine, New York University Medical Center, New York, NY 10016 6402, USA
    Annu Rev Immunol 24:771-800. 2006
    ..Thus, the Ras/MAPK pathway represents a clear example of compartmentalized signaling...
  97. ncbi Activation of c-K-ras mutations in human gastrointestinal tumors
    N Arber
    GI Oncology Unit, Tel Aviv University, Tel Aviv, Israel
    Gastroenterology 118:1045-50. 2000
    b>Ras genes are the most frequently detected oncogenes in human malignancies. Data regarding the frequency of c-K-ras mutations in esophageal, gastric, and small bowel tumors are limited and controversial.
  98. ncbi Different genetic pathways to proximal and distal colorectal cancer influenced by sex-related factors
    J Breivik
    Department of Immunology, Institute of Cancer Research, The Norwegian Radium Hospital, Oslo
    Int J Cancer 74:664-9. 1997
    ..0001). Our data confirm that different genetic pathways to colorectal cancer dominate in the proximal and distal segments of the bowel and suggest that the K-ras- and MIN-dependent pathways are influenced by different sex-related factors...
  99. ncbi LKB1 modulates lung cancer differentiation and metastasis
    Hongbin Ji
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Nature 448:807-10. 2007
    ..These studies establish LKB1 as a critical barrier to pulmonary tumorigenesis, controlling initiation, differentiation and metastasis...
  100. ncbi Genetic changes in skin tumor progression: correlation between presence of a mutant ras gene and loss of heterozygosity on mouse chromosome 7
    R Bremner
    Beatson Institute for Cancer Research, Bearsden, Glasgow, Scotland
    Cell 61:407-17. 1990
    ..included both nondisjunction and mitotic recombination events, were only seen in tumors that have activated ras genes. We conclude that gross chromosomal alterations that elevate the copy number of mutant H-ras and/or lead to loss ..
  101. ncbi High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis
    S Bezieau
    Laboratoire de Genetique Moleculaire, Institut de Biologie, Nantes, France
    Hum Mutat 18:212-24. 2001
    ..Thus, these early mutations could play a major role in the oncogenesis of MM and P-PCL...

Research Grants63

  1. Regulation of K-Ras by a Farnesyl-electrostatic Switch
    MARK REID PHILIPS; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Of the three ras genes, kras is most frequently mutated in human cancer...
  2. CPG METHYLATION AND MUTATION
    Gerd P Pfeifer; Fiscal Year: 2013
    ..In parallel, we will study molecular pathways involving the Polycomb repression complex that might operate during tumor progression to promote hypermethylation of CpG islands in malignant tissue. ..
  3. Novel CTD inhibitors with synthetic lethality to oncogenic Ras for cancer therapy
    Bingliang Fang; Fiscal Year: 2013
    ..We hypothesize that agents that induce synthetic lethality in cancer cells expressing oncogenic Ras genes but not in normal isogenic cells will be valuable prototypes for developing Ras-targeted anticancer therapeutics...
  4. Host Defense Mechanisms in Polyaromatic Hydrogen Carcinogenesis
    Craig A Elmets; Fiscal Year: 2013
    ..We have developed novel reagents and we utilize them as a vaccine to determine if they augment immunity to PAHs and can be used to prevent tumors from developing in the first place. ..
  5. Nanotheranostics for Early Colorectal Cancer Detection and Treatment
    Jeffrey S Souris; Fiscal Year: 2013
    ....
  6. Intervention of Pancreatic Oncogenic Pathways with Dietary Tocotrienol
    Mokenge P Malafa; Fiscal Year: 2012
    ..The results from these studies will advance our understanding of how a bioactive food component such as delta-tocotrienol can be exploited for the prevention and treatment of pancreatic cancer. ..
  7. Glypican-1 in gliomagenesis
    Andreas Friedl; Fiscal Year: 2013
    ..The GPC1 signaling pathway may offer opportunities for therapeutic intervention by targeting either GPC1 itself or downstream mediators. ..
  8. Dual Modality System for Imaging Colon Cancer in Mice
    Jennifer Kehlet Barton; Fiscal Year: 2013
    ..abstract_text> ..
  9. Epidermal stem cell properties in mice with altered polyamines
    Lisa M Shantz; Fiscal Year: 2010
    ..Information obtained from the proposed work will lead to future studies that address the broader question of what pathways are altered in follicular stem cells upon ODC downregulation. ..
  10. The role of pheomelanin in cutaneous melanoma
    Rutao Cui; Fiscal Year: 2013
    ..Third, we will map DNA damage in specific sequences of BRAF and N-RAS genes, both of which are frequently mutated in human melanoma...
  11. Pancreatic Cancer Management by Novel Gene Therapy &Dietary Agents
    Paul B Fisher; Fiscal Year: 2012
    ....
  12. Lysyl Oxidase Propeptide: Breast Cancer Inhibitor
    Gail E Sonenshein; Fiscal Year: 2013
    ....
  13. MicroRNAs and chromosome 22q in the colon
    Anil K Rustgi; Fiscal Year: 2012
    ..Our studies hope to reveal new paradigms in CRC pathogenesis, and offer opportunities for exploiting this knowledge in novel diagnostics and therapeutics. ..
  14. Crystallographic Studies of Electron Tranfer Proteins
    DOUGLAS CHARLES REES; Fiscal Year: 2012
    ..abstract_text> ..
  15. Measurements of BPDE-DNA adducts by solid state nonopore and deep sequencing (PQ
    Farhad Kosari; Fiscal Year: 2013
    ..The approaches introduced here can be extended to most other toxins and carcinogens that form DNA adducts. These findings will benefit diverse areas of cancer and scientific research, such as toxicology, where adducts are studied. ..
  16. Characterization of lcmt in Animal Models of Cancer
    MARK REID PHILIPS; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Ras genes are mutated in cancer more frequently than any other oncogene...
  17. Identification of Metabolic Vulnerabilities of Ras-Driven Cancer Cells
    Eileen White; Fiscal Year: 2013
    ..b>Ras genes are among the most frequently mutated oncogenes in cancer, and their mutational activation induces the Warburg ..
  18. Regulation of Ras signaling by the ubiquitin pathway
    Cathie M Pfleger; Fiscal Year: 2013
    ..The proposed studies will investigate a novel regulation of Ras by a process called "ubiquitination" and could contribute tremendously towards a better understanding of Ras and may have profound implications for cancer research. ..
  19. MutT Homolog 1 as a Novel Mediator of RAS Oncogene-Induced Pro-Malignant Pathways
    Priyamvada Rai; Fiscal Year: 2013
    ....
  20. GENE REGULATORY MECHANISMS OF EPIDERMAL GROWTH
    Paul A Khavari; Fiscal Year: 2013
    ..PUBLIC HEALTH RELEVANCE: This project seeks to understand mechanisms controlling gene expression within epidermis of skin which are important for controlling skin growth and differentiation. ..
  21. Melanocyte Survival and Transformation: Hypoxia & P13 Kinase/Akt/mTOR Signaling
    Marianne Broome Powell; Fiscal Year: 2010
    ....
  22. Growth/differentiation control of keratinocytes by ROR alpha
    Jun Dai; Fiscal Year: 2013
    ..Pharmacologically, we will test whether treatment with a ROR1 specific agonist (CGP 52608) can affect chemical- induced and/or xenograft tumor formation. ) ..
  23. A Mouse model of TGFbeta1 and ras oncogene interactions
    Adam B Glick; Fiscal Year: 2010
    ....
  24. RAS Signaling, Senescent Fibroblasts, and Ovarian Cancer Progression
    Jinsong Liu; Fiscal Year: 2012
    ..The improved understanding of the molecular mechanisms will be required for an eventual exploration of the therapeutic relevance of this observation. ..
  25. Understanding the Role of kB Ras Proteins in Signaling and Development
    Sankar Ghosh; Fiscal Year: 2013
    ..Our preliminary results using knock-outs of both (B-ras genes shows that they act to inhibit both NF-(B and Ral GTPase pathways...
  26. WORKER GENETIC SUSCEPTIBILITY TO MUTAGENIC RISK
    Paul W Brandt-Rauf; Fiscal Year: 2013
    ..Furthermore, since these same pathways are involved in the genetic damage due to many other workplace chemicals, this study could have wider significance for gene-environment interactions/interventions in the workplace generally. ..
  27. BIOLOGICAL ACTIVITY OF RAS ONCOGENES
    Channing J Der; Fiscal Year: 2013
    ..Therefore, we believe that our studies to better understand how this pathway, the RalGEF-Ral pathway, promotes Ras- driven cancer growth will lead to our identification of novel drugs for the effective treatment of pancreatic cancer. ..
  28. Evaluation of NF1 as a Major Breast Cancer Driver
    John C Schimenti; Fiscal Year: 2013
    ..Validation of this hypothesis would impact the treatment of patients with NF1-mutated breast cancers, and provide a powerful model for therapeutic development. ..
  29. Targeting Pten - An Upstream, Downstream and Offstream Approach
    ZE apos EV A RONAI; Fiscal Year: 2013
    ..abstract_text> ..
  30. Integrative genomic characterization of lung cancer metastasis in mouse and human
    Tyler E Jacks; Fiscal Year: 2013
    ..abstract_text> ..
  31. Direct inhibition of mutant K-Ras for the treatment of cancer
    Matt Patricelli; Fiscal Year: 2013
    ..If our approach is successful, our Phase II studies will more fully examine the safety, efficacy, and PK/biodistribution of a lead formulation for advancement to an IND application. ..
  32. Molecular Modeling of Pediatric Skeletal Muscle Tumors
    Corinne Mary Linardic; Fiscal Year: 2013
    ..In addition, this genetically defined model will serve as a template for the systematic investigation of other human sarcomas. ..
  33. Modeling ETP-ALL in mouse
    Gutian Xiao; Fiscal Year: 2013
    ..We will focus these studies on the role of activating mutations in Ras genes, since we have shown that ETP- ALLs in PDLIM2 KO mice harbor activating mutations in Ras genes, a known outcome ..
  34. Regulation of Ras by Monoubiquitination
    Sharon L Campbell; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): RAS genes comprise the most commonly mutated class of oncogenes in human cancer (33%)...
  35. Genetic and genomic analysis of Ras signaling in colorectal cancer progression
    KEVIN MICHAEL HAIGIS; Fiscal Year: 2010
    ..Through my functional studies of the K-RAS oncogene, I aim to identify molecular targets for novel therapeutics that will eradicate colon cancer. ..
  36. Role of Mitotic Checkpoint Defects in Mouse Tumor Models
    ROBERT I BENEZRA; Fiscal Year: 2010
    ..How chromosome instability contributes to the initiation and progression of disease will be explored. These experiments should allow us to shed further light on the role of mitotic checkpoint abnormalities in human disease. ..
  37. EFFECTS OF BENZO[A]PYRENE IN TRANSGENIC MODEL OF CERVICA
    ELLEN RORKE; Fiscal Year: 2002
    ..Use of our novel transgenic model provides an innovative approach for addressing these questions. ..
  38. CANCER CHEMOPREVENTION BY SILYMARIN
    Rajesh Agarwal; Fiscal Year: 1999
    ..The results of the proposed studies will identify a new agent with significant anti-tumor promoting effect, and will define in particular the Ha-ras mediated mechanism of such protective effect. ..
  39. Inhibiting oncogenic KRAS for cancer therapy
    Garth Powis; Fiscal Year: 2013
    ....
  40. K-Ras4A Trafficking and Signaling
    FREDERICK DEECHEN TSAI; Fiscal Year: 2013
    ..Of the three Ras genes, mutations in KRAS are the most frequently found in human tumors...
  41. SALIVARY GLAND TRANSGENIC MOUSE MODEL
    ELISA DURBAN; Fiscal Year: 1990
    ....
  42. REGULATION OF MITOSIS IN NORMAL AND TRANSFORMED CELLS
    Robert Schlegel; Fiscal Year: 1993
    ....
  43. DETECTION OF MINIMAL RESIDUAL DISEASE IN ACUTE LEUKEMIA
    Jerry Radich; Fiscal Year: 1993
    ..In sum, this proposal could broaden the understanding of the biology of leukemia, aid in its therapy, and provide support to an emerging clinical scientific career...
  44. Targeting HMGA1 in Pancreatic Tumor Progression
    Linda M S Resar; Fiscal Year: 2010
    ..In this grant, we propose studies to identify cellular pathways important in the development of pancreatic cancer with emphasis on those that could be targeted in therapy. ..
  45. SPECIFIC INHIBITION OF K-RAS EXPRESSION IN LUNG CANCER
    CHARLES MAYFIELD; Fiscal Year: 1999
    ..These studies will provide critical information on the potential for antigene therapy in humans. ..
  46. TRANSCRIPTIONAL INTERFERENCE AND TUMORIGENICITY
    Perry Kannan; Fiscal Year: 2000
    ..Abolition of AP-2 transcriptional self-interference using coactivators might reverse tumorigenicity of PA-1 cells induced by RAS oncogene and that would clearly establish the clinical importance of transcriptional coactivators. ..
  47. Novel Methods for Molecular Analysis of Colorectal Polyps
    James Han; Fiscal Year: 2006
    ..high sensitivity detection of both truncating and non-chain truncating (missense) mutations in the P53 and K-Ras genes. Evaluation of these techniques will be performed on DNA extracted from a repository of polyp tissue using full ..
  48. DIETARY HETEROCYCLIC AMINES, GENETIC SUSCEPTIBILITY, AND
    Maria Martinez; Fiscal Year: 2002
    ..This two-phase analysis provides a strong approach to address these study questions and enhance our understanding of the mechanisms related to the inherited susceptibility markers. ..
  49. FIBRONECTIN--PROTEOGLYCAN BINDING IN ADHESION SITES
    LLOYD CULP; Fiscal Year: 1993
    ....
  50. DNA Damage and Tobacco-Induced Lung Cancer
    ERIC MOON SHONG TANG; Fiscal Year: 2009
    ..The p53 and K-ras genes are two frequently mutated genes in TS-related lung cancers...
  51. TRANSFORMATION PROPERTIES OF THE HTLV-1 TAX GENE
    RUDY POZZATTI; Fiscal Year: 1992
    ..Once identified these genes will be analyzed to determine what role they may play in the development of a variety of human malignancies. ..
  52. PROTEASE INIBITORS SUPPRESSION OF ONCOGENE FUNCTION
    Seymour Garte; Fiscal Year: 1992
    ..Increased knowledge of oncogene transformation pathways, and development of a useful assay for the anti-neoplastic activity of protease inhibitors and other agents, are also likely to come from this research...
  53. CHEMICAL PROBES OF PROTEIN PRENYLATION
    Richard Gibbs; Fiscal Year: 2007
    ..abstract_text> ..
  54. DYSREGULATION OF DIFFERENTIATION IN RAS TRANSFORMED CELL
    MICHAEL TAINSKY; Fiscal Year: 2002
    ..abstract_text> ..
  55. FUNCTION OF RHOB PROTEIN
    George Prendergast; Fiscal Year: 1999
    ..by RhoB signaling activity; clone RhoB effector molecule(s); genetically inhibit candidate effector molecules in normal or ras- transformed cells to establish that their activity is necessary for normal or transformed cell growth ..
  56. ANALYSIS OF YEAST CAMP-DEPENDENT PROTEIN KINASE
    John Cannon; Fiscal Year: 1992
    ..A variety of oncogenes encode cellular protein kinases. The gene products of mammalian ras genes are not protein kinases, but they do function in yeast (Saccharomyces cerevisiae) to activate adenylate cyclase; ..
  57. INHIBITION OF HUMAN ONCOGENE EXPRESSION BY INTERFERON
    Robert Friedman; Fiscal Year: 2003
    ..The mechanism involved in this deletion will be investigated as it might be useful for the treatment of HTLV or HIV induced diseases, which involve LTR-linked viruses. ..
  58. EXPRESSION OF THE HUMAN C-K-RAS GENE
    Manuel Perucho; Fiscal Year: 1993
    ..of c-K-ras p21 with the ASP13 versus other mutations in vitro; 3) the relative oncogenic penetrance of c-K-ras genes with this and other mutations in vivo; and 4) the relative accessibility or sensitivity to carcinogens of c-K-..
  59. COOPERATIVE EFFECTS OF VIRAL AND CELLULAR ONCOGENES
    ELIZABETH TAPAROWSKY; Fiscal Year: 1993
    ....
  60. RAS ONCOGENE-RELATED PROTEINS AND SECRETION
    JAMES ROTHMAN; Fiscal Year: 1993
    ..Thus work is likely to be of significance for cell biology, and may also afford novel insights into the basis of malignant transformation...
  61. RAS ONCOGENE RELATED PROTEINS AND SECRETION
    JAMES ROTHMAN; Fiscal Year: 1999
    ..Thus work is likely to be of significance for cell biology, and may also afford novel insights into the basis of malignant transformation. ..
  62. STRUCTURE AND MECHANISM OF PROTEIN PRENYLTRANSFERASES
    LORENA BEESE; Fiscal Year: 2002
    ..abstract_text> ..
  63. FUNCTION OF THE PCPH ONCOGENE IN MAMM;CARCINOGENESIS
    Vicente Notario; Fiscal Year: 2007
    ..abstract_text> ..